ClinicalTrials.gg
CompletedNCT05152628Updated Mar 17, 2025

A Study of Modigraf® (Tacrolimus Granules) to Evaluate the Pharmacokinetics and Long-term Safety and Efficacy in De Novo Pediatric Allograft Liver and Kidney Transplantation Recipients

A Phase 4 interventional study of Tacrolimus granules and Tacrolimus granules in Liver Transplantation and Kidney Transplantation, sponsored by Astellas Pharma China, Inc.. Completed at 4 sites in China. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2025-03-17.

Sponsored by Astellas Pharma China, Inc. (part of Astellas Pharma Inc) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
55
Allocation
Not applicable
Ages
Up to 17 Years
Sex
All
01

Study summary

The purpose of this study is to determine the pharmacokinetics of tacrolimus following oral administration of Modigraf, after the first oral dose and at steady state in pediatric participants undergoing de novo allograft liver or kidney transplantation. This study will also observe the safety and efficacy of Modigraf in de novo pediatric allograft liver and kidney transplantation recipients.

Read the detailed description

Pediatric participants will be treated with a Modigraf (tacrolimus granules) based immunosuppressive regimen for 12 months.

02

Conditions studied

  • Liver Transplantation
  • Kidney Transplantation

Keywords

  • Liver Transplantation
  • Kidney Transplantation
  • Modigraf
  • Tacrolimus
  • Pediatric
  • Pharmacokinetics
03

In context

Lead sponsor

Astellas Pharma China, Inc. is the lead sponsor of 24 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant's parent(s) or their legal representative(s), and participant where applicable agrees not to participate in another interventional study while participating in the present study from 1 month before screening to the end of the study.

Exclusion criteria

Exclusion Criteria:

  • Participant has previously received another organ transplant.
  • Participant has a high immunological risk, defined as a panel reactive antibody (PRA) score > 50% in the previous 6 months (only applicable for kidney transplantation recipients).
  • Cold ischemia time of the donor kidney longer than 30 hours (only applicable for kidney transplantation recipients).
  • Bilateral kidney transplantation recipients (only applicable for kidney transplantation recipients).
  • Participant receives an ABO incompatible donor organ.
  • Participant has significant kidney impairment, defined as having serum creatinine ≥ 230 μmol/L (≥ 2.6 mg/dL) prior to transplantation (not applicable for kidney transplantation recipients).
  • Participant has significant liver disease, defined as having elevated (ALT) and/or aspartate aminotransferase (AST) and/or total (TBL) levels 3 times the upper value of the normal range prior to transplantation (not applicable for liver transplantation recipients).
  • Participants with or a history of malignancy within the last 5 years.
  • Participant has a significant, uncontrolled systemic infection and/or severe diarrhea, vomiting, active upper gastrointestinal disorder that may affect the absorption of tacrolimus or has an active peptic ulcer.
  • Recipient or donor known to be (HIV), virus (HCV), or virus (HBV) positive.
  • Participant requires systemic medication for any indication other than transplantation.
  • Participants taking or requiring to be treated with medication or substances prohibited by this protocol.
  • Known allergy or intolerance to , macrolide antibiotics, basiliximab, or tacrolimus.
  • Participants with severe primary disease/complications/poor general condition which may be unsuitable for participating in this study.
  • Participant is currently participating in another clinical trial and/or has been taking any other study drug within 1 month prior to screening.
  • Participant is unlikely to comply with the visits scheduled in the protocol.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    Liver Transplant

    Pediatric participants who undergo de novo allograft liver transplantation receive initial daily dose of 0.2 milligram per kilogram (mg/kg) of body weight oral suspension of tacrolimus granules post-operatively for 12 months.

    Drug: Tacrolimus granules

  • Experimental
    Kidney Transplant

    Pediatric participants who undergo de novo allograft kidney transplantation receive initial daily dose of 0.2 mg/kg of body weight oral suspension of tacrolimus granules post-operatively for 12 months.

    Drug: Tacrolimus granules

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK) of tacrolimus granules in whole blood: area under the blood concentration - time curve for a dosing interval (AUCtau) on Day 1

    AUCtau is recorded from the pharmacokinetic (PK) whole blood samples collected.

    Time frame: Predose, 0.5, 1, 2, 8, 12 hours post dose on day 1

  2. PK of tacrolimus granules in whole blood: AUCtau on Day 7

    AUCtau is recorded from the PK blood samples collected.

    Time frame: Predose, 0.5, 1, 2, 8, 12 hours post dose on day 7

  3. PK of tacrolimus granules in whole blood: maximum concentration (Cmax) on Day 1

    Cmax is recorded from the PK blood samples collected. Cmax is maximum concentration observed in an observation period.

    Time frame: Predose, 0.5, 1, 2, 8, 12 hours post dose on day 1

  4. PK of tacrolimus granules in whole blood: Cmax on Day 7

    Cmax is recorded from the PK blood samples collected. Cmax is maximum concentration observed in an observation period.

    Time frame: Predose, 0.5, 1, 2, 8, 12 hours post dose on day 7

  5. PK of tacrolimus granules in Whole Blood: Time of Maximum Concentration (Tmax) on Day 1

    Tmax is recorded from the PK blood samples collected. Tmax is time of maximum concentration in an observation period.

    Time frame: Predose, 0.5, 1, 2, 8, 12 hours post dose on day 1

  6. PK of tacrolimus granules in Whole Blood: Tmax on Day 7

    Tmax is recorded from the PK blood samples collected. Tmax is time of maximum concentration in an observation period.

    Time frame: Predose, 0.5, 1, 2, 8, 12 hours post dose on day 7

  7. PK of tacrolimus granules in whole blood: Trough blood concentration (Ctrough) on Day 1

    Ctrough is recorded from the PK blood samples collected.

    Time frame: Pre-dose on day 1

  8. PK of granules tacrolimus in whole blood: Ctrough on Day 7

    Ctrough is recorded from the PK blood samples collected.

    Time frame: Pre-dose on day 7

  9. Correlation between Ctrough and AUCtau of tacrolimus granules PK parameters in whole blood on Day 1

    The correlation between Ctrough and AUCtau PK parameters will be assessed by Pearson's coefficient at each sample time by visit.

    Time frame: Predose, 0.5, 1, 2, 8, 12 hours post dose on day 1

  10. Percentage of Participants With Acute Rejection (AR)

    AR is an immune response against the donor graft that causes tissue impairment and potential failure. The criteria for rejection is performed by the local histopathologist following the "Histological Grading of Liver Biopsies for Rejection", the "Banff diagnostic categories for renal allograft biopsies".

    Time frame: From first dose to month 12

  11. Number of Participants who Died

    Number of participant who died is recorded during 12 months' post-transplant; any cause of death is taken into account.

    Time frame: From first dose to month 12

  12. Number of Participants with Graft Failure

    Graft failure is defined as graft dysfunction, including re-transplantation or death, during the study period. A graft dysfunction to permanent dialysis in kidney transplantation is also considered as graft failure.

    Time frame: From first dose to month 12

  13. Number of Dose Adjustments Throughout the Study Period

    The dose adjustments required for the organ transplant is reported.

    Time frame: From first dose to month 12

  14. Number of Participants with Treatment Emergent Adverse Events (AEs)

    An AE is defined as any untoward medical occurrence in a participant given a study drug not necessarily linked to this treatment. An AE can be any unfavorable and unintended sign (e.g., abnormal laboratory finding; abnormal laboratory test result or other safety assessment, symptom, or disease) temporally associated with the use of study drug whether or not considered related to the study drug. Treatment emergent adverse event (TEAE) is defined as AE observed after administering the study drug.

    Time frame: From first dose to month 12

  15. Whole Blood Trough Levels of Tacrolimus

    Tacrolimus whole blood trough levels are routinely monitored from whole blood samples, using a local assay method, for example EMITÒ or Liquid-Chromatography-Mass-Spectrometry-Mass-Spectrometry (LC-MS-MS) in the local laboratories. Mean trough levels of tacrolimus from day 1 through month 12 are reported.

    Time frame: From day 1 through month 12 (predose)

  16. Correlation between Ctrough and AUCtau of tacrolimus granules in whole blood on Day 7

    The correlation between Ctrough and AUCtau is assessed by Pearson's coefficient at each sample time by visit.

    Time frame: Predose, 0.5, 1, 2, 8, 12 hours post dose on day 7

  17. PK of tacrolimus granules in Whole Blood: Dose-normalized AUCtau on Day 1

    Dose-normalized AUCtau is AUCtau normalized with the dose just prior to blood sampling. Dose-normalized AUCtau is calculated as AUCtau/dose.

    Time frame: Predose, 0.5, 1, 2, 8, 12 hours post dose on day 1

  18. PK of tacrolimus granules in Whole Blood: Dose-normalized AUCtau on Day 7

    Dose-normalized AUCtau is AUCtau normalized with the dose just prior to blood sampling. Dose-normalized AUCtau is calculated as AUCtau/dose.

    Time frame: Predose, 0.5, 1, 2, 8, 12 hours post dose on day 7

  19. PK of tacrolimus granules in Whole Blood: Dose-normalized Cmax on Day 1

    Dose-normalized Cmax is Cmax normalized with the dose just prior to blood sampling. Dose-normalized Cmax is calculated as Cmax/dose.

    Time frame: Predose, 0.5, 1, 2, 8, 12 hours post dose on day 1

  20. PK of tacrolimus granules in Whole Blood: Dose-normalized Cmax on Day 7

    Dose-normalized Cmax is Cmax normalized with the dose just prior to blood sampling. Dose-normalized Cmax is calculated as Cmax/dose.

    Time frame: Predose, 0.5, 1, 2, 8, 12 hours post dose on day 7

  21. PK of tacrolimus granules in Whole Blood: Dose-normalized Ctrough on Day 1

    Ctrough normalized with the dose just prior to blood sampling. Dose-normalized Ctrough is calculated as Ctrough/dose.

    Time frame: Predose, 0.5, 1, 2, 8, 12 hours post dose on day 1

  22. PK of tacrolimus granules in Whole Blood: Dose-normalized Ctrough on Day 7

    Ctrough normalized with the dose just prior to blood sampling. Dose-normalized Ctrough is calculated as Ctrough/dose.

    Time frame: Predose, 0.5, 1, 2, 8, 12 hours post dose on day 7

  23. Percentage of Participants With Biopsy-Proven Acute Rejections (BPAR)

    AR is an immune response against the donor graft that causes tissue impairment and potential failure. The criteria for rejection is performed by the local histopathologist following the "Histological Grading of Liver Biopsies for Rejection", the "Banff diagnostic categories for renal allograft biopsies". A BPAR episode is defined as any AR episode confirmed by biopsy.

    Time frame: From first dose to month 12

  24. Percentage of Participants With Clinically Suspected Rejection

    AR is an immune response against the donor graft that causes tissue impairment and potential failure. The criteria for rejection is performed by the local histopathologist following the "Histological Grading of Liver Biopsies for Rejection", the "Banff diagnostic categories for renal allograft biopsies". An AR is clinically suspected in participants who experienced an increase in serum creatinine, after the exclusion of other causes of graft dysfunction (generally with biopsy).

    Time frame: From first dose to month 12

07

Study locations

4 sites
  • Site CN86003
    Beijing, China
  • Site CN86002
    Guangzhou, China
  • Site CN86001
    Shanghai, China
  • Site CN86004
    Wuhan, China
08

References and documents

Individual participant data

Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Data sharing details ↗ · www.clinicaltrials.astellas.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2022 to primary completion in Mar 2024, 25 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2021
First posted
Dec 10, 2021
StartActual
Jan 11, 2022
Primary completionActual
Mar 6, 2024
CompletionActual
Mar 6, 2024
Last update
Mar 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05152628
Responsible party
Sponsor
First posted
Dec 10, 2021
Start date
Jan 11, 2022
Primary completion
Mar 6, 2024
Completion
Mar 6, 2024
Last update
Mar 17, 2025

Study contacts

Manager Medical Science
study director · Astellas Pharma China, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tacrolimus

Start the discussion